{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:12:41Z","timestamp":1771481561394,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Early death (ED), relapse, and second primary malignancies (SPMs) remain major barriers to both early and long-term outcomes in acute promyelocytic leukemia (APL). The prospective identification of key risk factors is essential to mitigate these adverse outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 174 consecutive patients with newly diagnosed APL treated at a single center, with a median follow-up of 59 months. We evaluated clinical, laboratory, and treatment-related factors associated with these outcomes, including comparisons across treatment eras and regimen categories, and we summarized institutional practice regarding central nervous system (CNS) prophylaxis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within the cohort, ED occurred in 9 patients, relapse in 7 patients, and SPMs in 7 patients. ED clustered with severe hemorrhagic and thrombotic complications during induction. Relapse was associated with subsequent adverse outcomes, including SPMs and death. Given the low number of events, multivariable modeling was restricted and interpreted cautiously with penalized approaches used as sensitivity analyses where applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings support the risk-adapted approach emphasizing prompt initiation of ATRA and intensified supportive care in patients with high-risk baseline features, alongside vigilant molecular and long-term surveillance to facilitate early detection and timely management of relapse and SPMs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1671705","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:23Z","timestamp":1771478603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors associated with early death, disease relapse and second primary malignancies in patients with newly diagnosed acute promyelocytic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Dong-Ming","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui-Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/204062071141077","article-title":"Emerging new approaches for the treatment of acute promyelocytic leukemia.","volume":"2","author":"Park","year":"2011","journal-title":"Ther Adv Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1007\/s00277-024-06014-1","article-title":"Different prognosis according to treatment in patients with acute promyelocytic leukemia: how the outcome changed over time.","volume":"103","author":"Scalzulli","year":"2024","journal-title":"Ann Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","article-title":"All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.","volume":"100","author":"Tallman","year":"2002","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.","volume":"118","author":"Park","year":"2011","journal-title":"Blood."},{"key":"B5","first-page":"1","article-title":"Early death in patients with acute promyelocytic leukemia. Proceedings from a live roundtable at the 2010 American Society of Hematology Annual Meeting, December 4\u20137, 2010, Orlando, Florida.","author":"Tallman","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/bloodadvances.2021004789","article-title":"Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study.","volume":"5","author":"Gill","year":"2021","journal-title":"Blood Adv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2217\/fon-2017-0077","article-title":"Second primary malignancy in acute promyelocytic leukemia: a surveillance, epidemiology and end results database study.","volume":"13","author":"Giri","year":"2017","journal-title":"Future Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb Haemost."},{"key":"B10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The retinoic acid syndrome in acute promyelocytic leukemia.","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern-Cooperative-Oncology-Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol-Canc."},{"key":"B13","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","article-title":"All-trans-retinoic acid in acute promyelocytic leukemia.","volume":"337","author":"Tallman","year":"1997","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","article-title":"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.","volume":"94","author":"Fenaux","year":"1999","journal-title":"Blood."},{"key":"B17","first-page":"3015","article-title":"A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RAR\u03b1-positive acute promyelocytic leukemia.","volume":"94","author":"Sanz","year":"1999","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.1998.16.1.78","article-title":"Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-retinoic acid and chemotherapy.","volume":"16","author":"Asou","year":"1998","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1182\/blood-2008-05-159632","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.","volume":"112","author":"Sanz","year":"2008","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cncr.33914","article-title":"Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: a time-trend analysis.","volume":"128","author":"Jamy","year":"2022","journal-title":"Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41408-022-00767-6","article-title":"Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia.","volume":"12","author":"Matsuda","year":"2022","journal-title":"Blood Cancer J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.3892\/ol.2018.7854","article-title":"Early mortality in acute promyelocytic leukemia: potential predictors.","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.blre.2017.09.001","article-title":"The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia.","volume":"32","author":"Jillella","year":"2018","journal-title":"Blood Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1182\/blood-2009-07-233387","article-title":"Very long-term outcome of acute promyelocytic leukemia after treatment with all-retinoic acid and chemotherapy: the European APL Group experience.","volume":"115","author":"Ad\u00e8s","year":"2010","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.blre.2014.07.001","article-title":"Acute promyelocytic leukemia: what is the new standard of care?","volume":"28","author":"Watts","year":"2014","journal-title":"Blood Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3109\/10428194.2013.868458","article-title":"Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.","volume":"55","author":"Dillon","year":"2014","journal-title":"Leukemia Lymphoma."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3390\/cancers12061444","article-title":"Impact of CD56 continuously recognizable as prognostic value of acute promyelocytic leukemia: results of multivariate analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 study and a review of the literature.","volume":"12","author":"Takeshita","year":"2020","journal-title":"Cancers."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1080\/10428194.2018.1516875","article-title":"An analysis of the impact of CD56 expression in acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.","volume":"60","author":"Sobas","year":"2019","journal-title":"Leukemia Lymphoma."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3109\/10428194.2014.953143","article-title":"Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-retinoic acid plus chemotherapy or with all-retinoic acid plus arsenic trioxide.","volume":"56","author":"Eghtedar","year":"2015","journal-title":"Leukemia Lymphoma."},{"key":"B30","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood.V86.9.3542.bloodjournal8693542","article-title":"Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.","volume":"86","author":"Pedersen-Bjergaard","year":"1995","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2019.7351","article-title":"Improving outcomes of acute promyelocytic leukemia in the current era: analysis of the SEER database.","volume":"18","author":"Murthy","year":"2020","journal-title":"J Natl Compr Canc Ne."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.3390\/cancers12123610","article-title":"Second primary malignancy after acute promyelocytic leukemia: a population-based study.","volume":"12","author":"Lenzi","year":"2020","journal-title":"Cancers."},{"key":"B33","doi-asserted-by":"publisher","first-page":"722614","DOI":"10.3389\/fmed.2021.722614","article-title":"Coagulopathy in acute promyelocytic leukemia: can we go beyond supportive care?","volume":"8","author":"Hambley","year":"2021","journal-title":"Front Med-Lausanne."},{"key":"B34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1671705\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:25Z","timestamp":1771478605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1671705\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1671705"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1671705","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1671705"}}